Two patients diagnosed with dementia with Lewy bodies (DLB) presented with prominent behavioral disturbances. The first patient experienced well-formed visual hallucinations, movement disorders, and cognitive decline and was increasingly resistant to care. He was treated with galantamine 4 mg bid, which was increased to 8 mg bid after four weeks. Improvements in behavior, attention, and cognition made it possible for this patient to be transferred back to long-term care after 32 days. The second patient had increasing confusion, fluctuating cognition, agitation, and psychosis. He was given donepezil initially, then switched to galantamine 4 mg bid. He was assessed as stable for discharge with improved behavior control after three weeks. Both patients also were receiving an atypical antipsychotic (quetiapine) and an antidepressant (venlafaxine and sertraline, respectively).
McKeith IG, Galasko D, Kosaka K, et al.: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology. 1996; 47(5): 1113-1124.
Kaufer DI, Catt KE, Lopez OL, et al.: Dementia with Lewy bodies: Response of delirium-like features to donepezil. Neurology.1998; 51(5): 1512-1512.
6.
Ballard C, Grace J, McKeith I, et al.: Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet. 1998; 351(9108): 1032-1033.
Samuel W, Caligiuri M, Galasko D, et al.: Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: A preliminary study. Int J Geriatr Psychiatry.2000; 15(9): 794-802.
9.
McKeith I, Del Ser T, Spano P, et al.: Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebocontrolled international study. Lancet. 2000; 356(9247): 2031-2036.
10.
Raskind MA, Peskind ER, Wessel T, et al: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000; 54(12): 2261-2268.
11.
Tariot PN, Solomon PR, Morris JC, et al.: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000; 54(12): 2269-2276.
12.
Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. BMJ. 2000; 321(7274): 1445-1449.
13.
Rockwood K, Mintzer J, Truyen L, et al.: Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial. J Neurol Neurosurg Psychiatry.2001; 71(5): 589-595.
14.
Edwards K, Hershey L, Lichter D, et al.: Galantamine in the management of dementia with Lewy bodies: A 24-week, open-label study. Poster presented at: 11th Congress of the International Psychogeriatric Association; August 17-22, 2003; Chicago, IL.
15.
Edwards KR, Hershey L, Wray L, et al.: Efficacy and safety of galantamine in patients with dementia with Lewy bodies: A 12-week interim analysis. Dement Geriatr Cogn Disord. 2004; 17(Suppl 1): 40-48.
16.
Holm A, Michel M, Stern GA, et al.: The outcomes of an inpatient treatment program for geriatric patients with dementia and dysfunctional behaviors. Gerontologist. 1999; 39(6): 668-676.
17.
Allen CK: Occupational therapy: Functional assessment of the severity of mental disorders. Hosp Community Psychiatry. 1988; 39(2): 140-142.
18.
Folstein MF, Folstein SE, McHugh PR: “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res.1975; 12(3): 189-198.
19.
Andrews W, Parker G, Barrett E: The SSRI antidepressants: Exploring their “other” possible properties. J Affect Disord.1998; 49(2): 141-144.
20.
Ballard CG, Court JA, Piggott M, et al.: Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. Conscious Cogn. 2002; 11(3): 461-474.
21.
Aarsland D, Ballard C, McKeith I, et al.: Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. J Neuropsychiatry Clin Neurosci.2001; 13(3): 374-379.
22.
Whitehouse PJ, Kalaria RN: Nicotinic receptors and neurodegenerative dementing diseases: Basic research and clinical implications. Alzheimer Dis Assoc Disord.1995; 9(Suppl 2): 3-5.
23.
Martin-Ruiz C, Court J, Lee M, et al.: Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types. Acta Neurol Scand Suppl. 2000; 176: 34-41.
